L
Lamellar Biomedical
Patent-protected medical and pharmaceutical products
About Lamellar Biomedical
Lamellar is a biotechnology company dedicated to developing innovative therapies for severe respiratory conditions, specifically idiopathic pulmonary fibrosis (IPF) and cystic fibrosis (CF). The company operates in the healthcare and pharmaceutical market, targeting patients suffering from these debilitating diseases. Lamellar's business model revolves around research and development of novel treatments, leveraging advanced technologies such as gene therapies and their proprietary Lamellasome platform. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies. The company serves a global client base, including healthcare providers, patients, and pharmaceutical partners. Lamellar aims to transform the treatment landscape for pulmonary diseases by providing effective and life-changing therapies.
Source: Dealroom company dataAt a glance
- Founded
- 2007
- Headquarters
- Warrington, United Kingdom
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Invesco
Scottish Enterprise Growth Investments
Tricapital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lamellar Biomedical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lamellar Biomedical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.